1149 related articles for article (PubMed ID: 27569654)
41. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
42. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
[TBL] [Abstract][Full Text] [Related]
43. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
44. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
45. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
46. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
Chuang CH; Liu CH; Lu TJ; Hu ML
Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
[TBL] [Abstract][Full Text] [Related]
47. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
Lin SW; Huang SC; Kuo HM; Chen CH; Ma YL; Chu TH; Bee YS; Wang EM; Wu CY; Sung PJ; Wen ZH; Wu DC; Sheu JH; Tai MH
Mar Drugs; 2015 Feb; 13(2):861-78. PubMed ID: 25668036
[TBL] [Abstract][Full Text] [Related]
48. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.
Xu Y; Lin H; Meng N; Lu W; Li G; Han Y; Dai X; Xia Y; Song X; Yang S; Wei Y; Yu L; Zhao Y
Br J Pharmacol; 2013 Aug; 169(8):1766-80. PubMed ID: 23594209
[TBL] [Abstract][Full Text] [Related]
49. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
[TBL] [Abstract][Full Text] [Related]
50. Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway.
Ji L; Wu M; Li Z
Molecules; 2018 Aug; 23(8):. PubMed ID: 30111763
[TBL] [Abstract][Full Text] [Related]
51. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
52. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
[TBL] [Abstract][Full Text] [Related]
54. Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.
Kim MH; Jeong YJ; Cho HJ; Hoe HS; Park KK; Park YY; Choi YH; Kim CH; Chang HW; Park YJ; Chung IK; Chang YC
Oncol Rep; 2017 Feb; 37(2):777-784. PubMed ID: 27959445
[TBL] [Abstract][Full Text] [Related]
55. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway.
Watari K; Nakamura M; Fukunaga Y; Furuno A; Shibata T; Kawahara A; Hosoi F; Kuwano T; Kuwano M; Ono M
Int J Cancer; 2012 Jul; 131(2):310-21. PubMed ID: 21826646
[TBL] [Abstract][Full Text] [Related]
56. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells.
Xing Y; Tu J; Zheng L; Guo L; Xi T
Oncol Rep; 2015 Jan; 33(1):163-70. PubMed ID: 25376085
[TBL] [Abstract][Full Text] [Related]
57. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
58. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway.
Ding Q; Tian XG; Li Y; Wang QZ; Zhang CQ
World J Gastroenterol; 2015 Aug; 21(32):9566-76. PubMed ID: 26327764
[TBL] [Abstract][Full Text] [Related]
59. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
60. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
